ALLpaQ is proud to confirm that we have successfully renewed our ISO 9001:2015 certification (Cert. 23250). This milestone wouldn’t have […]
Jan 26th, 2024
Jan 26th, 2024
Baxter International has agreed to acquire Chatham Therapeutics LLC, a private biotechnology company which specialises in gene therapy programmes for haemophilia.
The deal, which is valued at around $70 million initially, could see future payments made to Chatham based on development, regulatory and commercial milestones.
Ludwig Hantson, president of Baxter’s BioScience unit, said the acquisition would help further the development of treatments for the blood-clotting disorder haemophilia.
“Chatham’s gene therapy platform technology offers the potential to redefine treatment of both haemophilia A and B,” he explained in a statement.
“This technology will be highly complementary to our expanding pipeline of bleeding disorder treatments as we continue our pursuit of a bleed-free world.”
Baxter and Chatham first partnered back in May 2012 to develop potential treatments for haemophilia B.
Jade Samulski, co-founder of Chatham, added: “Given Baxter’s long-standing commitment to innovative product development in haemophilia, we are confident that this transaction provides the best opportunity for the advancement of our BNPTM gene therapy platform technology for the benefit of haemophilia patients worldwide.”
The news comes shortly after Baxter announced plans to split itself into two separate healthcare companies with one focusing on biopharmaceuticals and the other on medical products.